NCT00559429View on ClinicalTrials.gov

Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Prostate Cancer
Interventions
DRUG

Docetaxel

Docetaxel 50mg/m2 IV on day 1 and day 22

DRUG

Docetaxel

Docetaxel 75mg/m2 IV on day 1 and day 22

DRUG

Docetaxel

Docetaxel 75mg/m2 IV on day 1 and day 22

DRUG

Docetaxel

Docetaxel 75 mg/m2 IV on day 1, 22 and day 43

Trial Locations (1)

21231

The Harry and Jeanette Weinberg Building, Baltimore

Sponsors

Collaborators (2)

Sanofi
Cytogen Corporation
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Cytogen Corporation

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER